Stock 600420 SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Shanghai Shyndec Pharmaceutical Co., Ltd. Share Price

Equities

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 26/04/2024 am IST 		5-day change 1st Jan Change
10.61 CNY -0.66% Intraday chart for Shanghai Shyndec Pharmaceutical Co., Ltd. +1.14% +8.38%
16/04 Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets MT
15/04 China stocks rise after new guidelines; HK shares drop RE

Financials

Sales 2024 * 13.35B 1.84B 154B Sales 2025 * 14.69B 2.03B 169B Capitalization 14.23B 1.96B 164B
Net income 2024 * 863M 119M 9.94B Net income 2025 * 996M 138M 11.47B EV / Sales 2024 * 1.07 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 0.97 x
P/E ratio 2024 *
16.6 x
P/E ratio 2025 *
14.3 x
Employees 11,608
Yield 2024 *
14.1%
Yield 2025 *
17%
Free-Float 39.64%
More Fundamentals * Assessed data

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Shanghai Shyndec Pharmaceutical Co., Ltd.

Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets MT
China stocks rise after new guidelines; HK shares drop RE
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator MT
Shyndec Pharma's Unit Gets Regulatory Nod for Sheep Vaccine MT
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan MT
China Grants Supplementary Drug Approval for Shyndec Pharmaceutical Subsidiaries' Antibiotic, Hypertension Tablets MT
Shyndec Pharma Passes Drug GMP Compliance Inspection MT
Shyndec Pharmaceutical's Drug Chosen for China's Centralized Bid MT
Shyndec Pharmaceutical Unit's Cefprozil Tablets Passes Regulatory Evaluation MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shyndec Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride's Listing MT
More news

Quotes and Performance

1 day-0.66%
1 week+1.14%
Current month+18.68%
1 month+19.08%
3 months+16.34%
6 months+3.21%
Current year+8.38%
More quotes

Highs and lows

1 week
10.15
Extreme 10.15
10.76
1 month
8.53
Extreme 8.53
10.76
Current year
7.61
Extreme 7.61
10.76
1 year
7.61
Extreme 7.61
13.91
3 years
7.61
Extreme 7.61
14.30
5 years
7.61
Extreme 7.61
14.30
10 years
7.61
Extreme 7.61
30.33
More quotes

Managers and Directors - Shanghai Shyndec Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Wan Yong Lian PSD
 President 54 24/22/24
Hao Li DFI
 Director of Finance/CFO 59 18/16/18
Qian Yin Jing IRC
 Investor Relations Contact 44 13/19/13
Members of the board TitleAgeSince
Yong Gang Xing CHM
 Chairman 48 25/19/25
Yong Liu BRD
 Director/Board Member 55 17/21/17
Shu Yuan Wei BRD
 Director/Board Member 60 29/20/29
More insiders

ETFs positioned on Shanghai Shyndec Pharmaceutical Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.14% -
More ETFs positioned on Shanghai Shyndec Pharmaceutical Co., Ltd.

Quotes

Date Price Change Volume
26/24/26 10.61 -0.66% 24,159,470
25/24/25 10.68 +2.69% 32,644,090
24/24/24 10.4 +0.39% 26,739,850
23/24/23 10.36 -1.52% 24,845,240
22/24/22 10.52 +0.29% 33,565,740

End-of-day quote Shanghai S.E., April 26, 2024

More quotes

Company Profile

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.
Sector
Pharmaceuticals
Calendar
30/04/2024 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
10.61
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
MERCK KGAA Stock Merck KGaA
+3.96% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+3.90% 1.65B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600420 Stock